Gilead Sciences (GILD) Goodwill & Intangibles (2009 - 2026)

Gilead Sciences (GILD) reported Goodwill & Intangibles of $24.7 billion for Q1 2026, down 10.74% on a YoY basis from $27.7 billion in Q1 2025, and down 2.36% quarter-over-quarter from $25.3 billion in Q4 2025.

Gilead Sciences (GILD) Goodwill & Intangibles (2009 - 2026) Analysis & Trends

Gilead Sciences has reported Goodwill & Intangibles for 18 years, with the latest figure at $24.7 billion in Q1 2026.

  • For the quarter ending Q1 2026, Goodwill & Intangibles fell 10.74% year-over-year to $24.7 billion; the trailing twelve-month figure through Mar 2026 stood at $24.7 billion (down 10.74% YoY), and the FY2025 full-year result was $25.3 billion, down 10.51% from the prior year.
  • Goodwill & Intangibles for Q1 2026 stood at $24.7 billion, down from $25.3 billion in the prior quarter.
  • The five-year high for Goodwill & Intangibles was $38.6 billion in Q1 2022, with the low at $24.7 billion in Q1 2026.
  • Historically, Goodwill & Intangibles has averaged $32.1 billion across 5 years, with a median of $31.7 billion in 2024.
  • Annual changes were most pronounced in 2023 — Goodwill & Intangibles decreased 5.13% — and 2024, when it declined 18.71%.
  • Gilead Sciences' Goodwill & Intangibles stood at $37.2 billion in 2022, then declined by 6.56% to $34.8 billion in 2023, then decreased by 18.71% to $28.3 billion in 2024, then decreased by 10.51% to $25.3 billion in 2025, then decreased by 2.36% to $24.7 billion in 2026.
  • The last three Goodwill & Intangibles figures came in at $24.7 billion (Q1 2026), $25.3 billion (Q4 2025), and $26.3 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 24.70 Bn
Dec 31, 2025 25.29 Bn
Sep 30, 2025 26.28 Bn
Jun 30, 2025 26.88 Bn
Mar 31, 2025 27.67 Bn
Dec 31, 2024 28.26 Bn
Sep 30, 2024 28.86 Bn
Jun 30, 2024 31.15 Bn
Mar 31, 2024 31.74 Bn
Dec 31, 2023 34.77 Bn
Sep 30, 2023 35.47 Bn
Jun 30, 2023 36.06 Bn
Mar 31, 2023 36.66 Bn
Dec 31, 2022 37.21 Bn
Sep 30, 2022 37.75 Bn
Jun 30, 2022 38.20 Bn
Mar 31, 2022 38.65 Bn
Dec 31, 2021 41.79 Bn
Sep 30, 2021 42.23 Bn
Jun 30, 2021 42.68 Bn